Should patients pay high-cost sharing for treatments for the Hepatitis C Virus?
Treatments for the hepatitis C virus (HCV) are expensive. At one point they cost over $80,000 per year, although costs have decreased since then. To prevent moral hazard, should insurance companies rely on cost sharing to decrease utilization? An article by Lakdawalla, Linthicum, and Vanderpuye-Orgle (2016) argues that they shouldn’t. Cost sharing appears even less efficient when…